A search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid dividends.
An article from
News roundup
A search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid off.
Published June 18, 2026
Getty Images
Pfizer Announces Chief Financial Officer Transition
Pfizer hunts for new CFO as Denton prepares to hang up gloves, wave goodbye to pharma
Pfizer CFO Dave Denton to leave company in August
Pfizer Stock Drops Today As CFO Steps Down In August - Pfizer (NYSE:PFE)
FDA appears open to Moderna's flu vaccine ahead of adcomm
Lilly's Ajax acquisition may have been worth it
Pfizer Announces Chief Financial Officer Transition
Pfizer’s chief financial officer Dave Denton will soon wave goodbye to the world of pharma, pivoting back to the consumer goods…
Pfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's…
Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its…
A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…
